کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت‌های کاربردی در تدوین و چاپ مقاله
Molecular profile of colorectal cancer in Indonesia: is there another pathway?

Murdani Abdullah, Aru Wisaksono Sudoyo, Ahmad R Utomo, Ahmad Fauzi, Abdul Aziz Rani
Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia

ABSTRACT
Colorectal cancer is an emerging public health problem in Indonesia and currently ranks among the three highest cancers. The age-standardized incidence rates of CRC per 100,000 populations in Indonesia were 19.1 for men and 15.6 for women (1). These rates are much lower than the incidence rates in Australia, New Zealand and Western Europe, but the number of cases is high because Indonesia ranks the fourth most populated country in the world with more than 235 million populations.

Previous epidemiological studies have shown that CRC patients in Indonesia are younger than patients in developed countries. More than 30% of cases were 40 years old or younger (2), while patients younger than 50 years in developed countries accounted for only 2-8% (3,4). In

Background
Colorectal cancer (CRC) is an emerging public health problem in Indonesia and currently ranks among the three highest cancers. Lack of a colonoscopy screening and lifestyle changes might contribute to it. In the last few decades, there is an increasing interest towards the contribution of genetic-environment interaction in colorectal carcinogenesis. Some studies have indicated that CRC might develop through several different pathways; the three major routes are chromosomal instability (CIN), microsatellite instability (MSI), and inflammatory pathways. An earlier study on clinical epidemiology of CRC in Indonesia showed that the majority of patients were diagnosed between 45 and 50 years old, with a mean age around 47 years old. Further studies showed that most young Indonesian cases of CRC do not have hereditary characteristics; however, the CRC did not follow the conventional pathways of sporadic CRC (the CIN) pathway. Rather, it is a mixed of MSI and inflammatory pathways. Immunohistochemical studies showed that the proportion of patients with negative mismatch repair proteins was 43.5% for MSH2 and 83.5% for MLH1. Along the sporadic colorectal carcinogenesis pathway, there was a specific role of cyclooxygenase-2 (COX-2) enzyme during the polyp formation. COX-2 expression was reported in about 80% CRC cases worldwide. However, our study found only 49% of COX-2 expression among the CRC patients. Interestingly, an inflammatory marker, the nucleus factor κB (NF-κB), was expressed in about 73.5% cases, in line with a previous study. More recently, KRAS has been used as a potential tumor marker to select treatment and its expression was reported to be as high as 30%-40% worldwide. However, we found that KRAS gene expression was only 16.3%. Our findings support that CRC patients in Indonesian might follow a distinct pathway, a hypothesis that deserves further exploration.

Keywords: Colorectal cancer, Molecular profile, Indonesia.

(Please cite as: Abdullah M, Sudoyo AW, Utomo AR, Fauzi A, Rani AA. Molecular profile of colorectal cancer in Indonesia: is there another pathway? Gastroenterol Hepatol Bed Bench 2012;5(2):71-78.)
addition, whereas young or early onset CRC in
developed countries are often associated with
familial cases (5,6), most Indonesian CRC patients
are determined to be sporadic. With the increasing
number of cases and the occurrence of CRC
during a person’s productive years, it is obvious
that CRC poses a major public health problem in
Indonesia.

Early onset CRC in developed countries
showed typical characteristics such as proximal
localization (ascending colon), low pathological
stage, rarely metastasize, and has better prognosis
(7). However, our patients showed otherwise
characteristics, i.e. distal localization (rectum),
high clinical stage, and poor survival (unpublished
data). All these observations have raised questions
regarding the carcinogenesis pathways of CRCs in
Indonesia.

Genomic instability in colorectal cancer
Classically, CRC is believed to develop from
an adenoma, the so-called adenoma-carcinoma
sequence (8,9). Epithelial malignant
transformation occurs after the cell underwent
genomic instability, which promotes the
accumulation of genetic and epigenetic alterations
without obvious phenotypic changes (10). Genomic instability is the prerequisite of CRC
development which allows multiple, gradual
genetic mutations (11). There are two distinct
pathways that marked the genomic instability, i.e.
the microsatellite instability (MSI) and the
chromosomal instability (CIN) pathways.

MSI is recognized as genome-wide alterations
in repetitive DNA sequence (12). It is found in
almost all malignancies from patients with
hereditary non-polyposis colorectal cancer
(HNPCC) and approximately 15% of the sporadic
cancers (13). MSI is caused by defects in the
nucleotide mismatch repair (MMR) mechanisms.
Mismatch repair enzymes normally recognize
errors in nucleotide matching of complementary
chromosome strands and initiate segmental
excision of the newly synthesized strand to ensure
faithful strand replication.

CIN is the most common type of genomic
instability and is associated with loss of
heterozygosity in various tumor suppressor loci,
especially 18q (14). Alterations range from
different types of chromosomal rearrangements, to
loss and gain of large fragments of the genome
and may have abnormal number of chromosomes
or DNA content (aneuploidy).

The role of epigenetic alterations
DNA methylation refers to the methylation of
cytosine (C) nucleotide preceding guanine (G)
nucleotide (CpG islands) throughout the genome,
preferentially in gene promoter regions. This
alteration may inactivate tumor suppressor genes,
thereby promoting cancer. In colorectal cancer,
DNA methylation may inactivate the MMR gene
hMLH1 gene leading to microsatellite instability
(15). Both hypomethylation of the genome and
simultaneous hypermethylation of the promoter
regions of strategic genes frequently occur (16).

Pathways to Colorectal Cancers
Colorectal cancer is a heterogeneous disease
and may arise through at least three main
pathways, namely sporadic, hereditary and
inflammation-associated cancers. These pathways
harbor distinct genetic alterations although they
may share some common mutations.

Hereditary Non-Polyposis Colorectal Cancer
(HNPCC)
HNPCC accounts for about 1-8% of all CRC
cases based on clinical criteria, i.e. the Amsterdam
criteria and the revised Bethesda guidelines (17-
19). Pathogenesis of familial or hereditary CRC
involved germ-line mutations of mismatch repair
(MMR) gene family members and was named
Microsatellite instability (MSI) pathway (20,21). Mutation of MMR genes such as hMLH1 and hMSH2 range from 0.3% to 3% of total CRC burden (22). However, hMLH1 and hMSH2 gene mutations account for more than 90% of HNPCC cases, with the remaining mutations occur in other MMR genes such as hMSH6, hPMS1, and hPMS2 (23).

**Sporadic Colorectal Cancer**

Most sporadic CRC follow the path of chromosomal instability (CIN) (24) that involved somatic mutation in adenomatous poliposis coli (APC) gene and other mutations which have been described as vogelstein adenoma-carcinoma sequel. This pathway is also known as the classical pathway, which involves mutation in APC, KRAS, and p53 genes, loss of 18q and deletion of 17p which harbor tumor suppressor gene p53 locus (8).

Mutations in the APC gene on chromosome 5q21 locus are considered the earliest events of colorectal carcinogenesis and constitutes between 60% and 80% of sporadic colorectal carcinoma and adenomas (25). Allelic loss of chromosome 18q21, which contains DCC, SMAD2, and SMAD4, is found in up to 60% of CRCs. Mutation of SMAD4 may be more influential in colorectal carcinogenesis and marked the divergence of chromosomal instability (CIN) from the microsatellite instability (MSI) pathway (26). A small proportion of sporadic CRCs, however, contains mutation in MMR genes and showed high MSI (MSI-H).

The reported incidences of KRAS and BRAF mutations in CRC were 37% and 13% of respectively (27,28). The frequency of KRAS mutation was different among HNPCC, MSS, and MSI-H CRC cases. HNPCC and sporadic MSI-H tumors without hMLH1 hypermethylation shared similar KRAS mutation frequency. These findings suggested that KRAS mutation frequency depends on the genetic or epigenetic mechanism (29).

Mutation in BRAF gene, another member of the RAS/RAF/MAPK pathway, is also crucial in colorectal tumorigenesis and co-occurrence with KRAS mutation in the same individual patient is a rare case (30,31). The frequency of V600E mutation in BRAF has been described in about 35% of sporadic MSI-H CRCs and about 6% in CRC without MMR deficiency or microsatellite stable (MSS) CRCs (32-34). Moreover, BRAF mutation is associated with hMLH1 promoter hypermethylation (34,35). While KRAS gene is mutated in about 20% of sporadic MSI-H and of 35% of MSS CRCs negative for the BRAFV600E mutation (32,33,36).

**Colitis-Associated Cancer**

Inflammation has been associated with cancer since the observation of leukocyte infiltrations in neoplastic tissues by Rudolf Virchow in 1863 (37). Inflammation could alter the dynamics of colonic epithelial cells growth, either their promoting survival or preventing apoptosis (38). Studies have shown a relationship between colonic inflammation and cancer incidence as indicated in context of ulcerative colitis and Crohn disease, the so-called inflammatory bowel disease (IBD). Colorectal cancer arising from IBD mostly occurs from a dysplastic precursor forming a flat adenoma, instead of polyp (39,40).

Besides genes classically known to be involved in sporadic colorectal carcinogenesis, patients with IBD also showed overexpression of inflammatory genes, such as the cyclooxygenase 2 (COX-2) genes (41) and nuclear factor kappa B (NF-κB) (42). COX-2 enzyme plays important role in producing prostaglandin E2 (PGE2), which stimulates cascades of signaling pathways leading to tumor growth, such as activation of phosphotidilinositol-3-kinase (PI3) and Wnt/β-catenin pathways (43). COX-2 is expressed in 40% of colorectal adenomas and 85% of sporadic CRC (44). Early molecular studies showed that colorectal tumors expressed high level of mRNA
(86%), while in normal colon mucosa, its expression is low or absent (45,46). High expression of COX-2 in sporadic CRC indicated its important role in colorectal carcinogenesis, which probably occurs early during the formation of adenomatous polyp (47).

Activation of NF-κB has been described in Crohn’s disease, ulcerative colitis, self-limited colitis, and experimental colitis (48,49). Nuclear factor kappa B is the most important component of inflammatory signaling pathway that may promote tumorigenesis. It is a central transcription factor activated by inflammatory signals in response to infectious agents, cytokines, and necrotic cellular remnants (50). Activation of NF-κB leads to the overexpression of cell cycle genes, apoptosis inhibitor and proteases; all of which may trigger invasive phenotypes. Immunohistochemical staining of RelA protein, the p65 component of NF-κB, found a significant difference of NF-κB expression among normal colorectal mucosa (9.3%), colorectal adenoma (54.0%), and colorectal adenocarcinoma (71.9%) (51).

**Molecular characteristics of CRC in Indonesia**

**MSI and CIN pathways**

Most CRC patients in Indonesia are sporadic, even though they were 40 years old or less. Early study showed that the expression of MMR proteins did not differ between young (40 years or less) and old (60 years or more) patients. Moreover, MSH2 and MLH1 were not expressed in 43.5% and 83.5% of cases, respectively hinting toward a defect in DNA mismatch repair system which may promote microsatellite instability (52). However, when tested using BAT26, a surrogate markers of MSI our samples showed very low frequency of MSI that is consistent with sporadic cancer feature. The low expression of normal MMR protein may be caused by epigenetic silencing event of DNA methylation in the promoter regions of MMR genes, which are known to occur in sporadic CRC patients (53). If this is true, then young CRC patients in Indonesia conform to sporadic molecular feature and may not use the MSI pathway, in spite of the large proportion of patients showing low expression of MMR genes. To test this hypothesis, we have evaluated the same specimens for SMAD4 protein expression. None of these tumors stained positive for SMAD4, either young or older patients, confirming that they are not following the MSI pathway.52

**Oncogenic mutation of KRAS and BRAF genes**

Our preliminary study found that only 16.3% of of 43 sporadic CRC cases harbored KRAS mutation and no BRAF mutation (54). This low KRAS mutation may indicate a different pattern of genetic instability in these colorectal tumors. The absence of BRAF gene mutation suggested that the samples may not belongs to the MSI-H group, which also associated with high methylation of hMLH1 gene promoter. However, we have not analyzed the methylation pattern of our samples, while studies assessing the mutation loci of the KRAS gene are still ongoing.

**Inflammatory pathways**

Using immunohistochemistry technique, we found that NF-κB was expressed in 73.5% of CRC specimens, whereas COX-2 expression was found in only 49.0% cases (55). The COX-2 expression may be considered as low since most studies in sporadic CRC found at least 80% of cases expressed COX-2 in the cytoplasm (44-46, 56). Our further analysis found that there was a significant association between COX-2 and NF-κB expressions (bivariate analysis p<0.001 and degree of agreement of 74%). The intensity score was also significantly correlated (r=0.941; p<0.001) (57). Other study also found a high correlation between COX-2 and RelA (p65) component of NF-κB expression (r=0.83; p<0.05)
The NF-κB is an important transcription factor to activate \textit{COX-2} gene expression. The 5’-UTR region of \textit{COX-2} gene promoter contains regulatory binding sites of several transcription factors, including two NF-κB binding site motifs (59).

Our study supports the hypothesis that inflammation may play roles in Indonesian CRC patients. However, the role of IBD in our subjects has not been proven yet. \textit{COX-2} was also expressed in moderate percentage (23.9%) in normal mucosa of our specimens (57), indicating the presence of chronic inflammation of unknown etiology (non-specific colitis). The role of normal gut flora as the etiology of CRC is difficult to be shown. However, experiment in mice suggested that the normal gut flora may play a role in colitis-associated carcinoma (60).

### Is there another pathway?

Studies elucidating the molecular pathway of colorectal carcinogenesis in Indonesia have just begun. Besides the three main pathways mentioned above, there are several minor pathways. Serrated pathway is believed to arise in serrated adenoma and genetically associated with \textit{BRAF} gene mutations exhibiting extensive DNA methylation but lacking \textit{APC} gene mutations (61). The serrated adenoma is a precursor lesion of sporadic CRC with high microsatellite instability (MSI-H), which constitutes approximately 15% of sporadic colon cancers (62). However, the absence

### Table 1. Summary of clinicopathology and genetic alterations of various colorectal carcinogenesis pathways

|                  | Sporadic | HNPCC | CAC | Serrated pathway | Sporadic indonesia? |
|------------------|----------|-------|-----|------------------|---------------------|
| **Age**          | >60 years| <40 years|     | Young            | Young              |
| **Location**     | Distal   | Proximal | Inflammation- dysplasia-cancer | Hyperplastic polyp-cancer | Distal |
| **Pathway**      | Adenoma-carcinoma | Adenoma-carcinoma | Inflammation- dysplasia-cancer | Hyperplastic polyp-cancer | Adenoma-carcinoma |
| **CIN**          |          |        | No  | Yes              | No                  |
| **Defective MMR**| No       | Yes   | No  | Yes              | Yes                |
| **MSI**          | No       | Yes   | No  | Yes              | No                  |
| **Inflammation** | No       | No    | IBD | No               | Non-specific?      |
| **Adenoma**      | Polyp    | Polyp | No  | Serrated adenoma | Polyp               |
| **KRAS mutation**| Yes      | Yes   | Yes | Yes              | No                  |
| **BRAF mutation**| No       | No    | No  | Yes              | No                  |
| **COX-2**        | No       | High  |     |                  |                     |
| **NF-κB**        | Yes      | No    | Yes | ?                | Yes                |
of BRAF mutation in our preliminary study does not support the notion that our CRC patients might take this pathway. Studies are still ongoing to tract their genetic alteration patterns. The summary of clinicopathological aspects and genetic mutation associated with various CRC pathways is given in Table 1 along with the proposed unanswered question on Indonesian CRCs. It seems that colorectal carcinogenesis in our population is still far beyond from common understanding and more genetic studies are needed to reveal the heterogeneous mechanisms of its process.

References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; in press.
2. Departemen Kesehatan RI. Laporan Tahunan Kanker: Direktorat Jendral Pelayanan Medik dan Perhimpunan Patologi Anatomi Indonesia. Jakarta: Depkes RI; 1995.
3. Parramore JB, Wei JP, Yeh KA. Colorectal cancer in patients under forty: presentation and outcome. Am Surg 1998;64: 563-67.
4. Lee PY, Fletcher WS, Sullivan ES, Vetto JT. Colorectal cancer in young patients: characteristics and outcome. Am Surg 1994;60: 607-12.
5. Turkiewicz D, Fletcher WS, Sullivan ES, Vetto JT. Colorectal cancer in young patients: characteristics and outcome. Am Surg 1994;60:607-12.
6. Chung YF, Eu KW, Machin D, Ho JM, Nyam DC, Leong AF, et al. Young age is not a poor prognostic marker in colorectal cancer. Br J Surg 1998;85: 1255-9.
7. Muta H, Noguchi M, Perrucio M, Ushio K, Sugihara, Ochiai A, et al. Clinical implications of microsatellite instability in colorectal cancer. Cancer 1996; 77:265-70.
8. Vogelstein B. Genetic alterations during colorectal tumor development. N Engl J Med 1988; 319:525-32.
9. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-67.
10. Schneider BL, Kulesz-Martin M. Destructive cycles: the role of genomic instability and adaptation in carcinogenesis. Carcinogenesis 2004; 25:2033-44.
11. Stoler DL, Chen N, Basik M, Kahlenberg MS, Rodriguez-Bigas MA, Petrelli NJ, et al. The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc Natl Acad Sci USA 1999; 96:15121-26.
12. Lothe RA. Microsatellite instability in human solid tumors. Mol Med Today 1997; 3:61-68.
13. Breivik J, Gaudernack G. Genomic instability, DNA methylation, and natural selection in colorectal carcinogenesis. Cancer Biol 1999; 9:245-54.
14. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386:623-7.
15. Kane MF, Loda M, guida GM, Lipman J, Mishra R, Goldman H, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997;57:808-11.
16. Bariol C, Suter C, Cheong K, Ku SL, Meagher A, Hawkins N, et al. The relationship between hypomethylation and CpG island methylation in colorectal neoplasia. Am J Pathol 2003; 162:1361-71.
17. Aaltonen LA, Sankila R, Mecklin JP, Jarvinen H, Pukkala E, Peltomaki P, et al. A novel approach to estimate the proportion of hereditary nonpolyposis colorectal cancer of total colorectal cancer burden. Cancer Detect Prev 1994; 18:57-63.
18. Vasen H. Clinical diagnosis and management of hereditary colorectal cancer syndromes. J Clin Oncol 2000; 18: 81s-92s.
19. Cravo ML. Validation and simplification of Bethesda guidelines for identifying apparently sporadic forms of colorectal carcinoma with microsatellite instability. Cancer 1999; 85:779-85.
20. Lynch HT, de-la-Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999; 36:801-18.
21. Salovaara R, Loukola A, Kristo P, Kaaraihnen I, Ahtola H, Eskelinen M, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000; 18:2193-200.
22. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998; 338:1481-87.
23. Mitchell RJ, Farrington SM, Dunlop MG, Campbell H. Mismatch repair genes hMLH1 and hMSH2 and colorectal cancer: A huge review. Am J Epidemiol 2002; 156:885-902.
24. Breivik J. The evolutionary origin of genetic instability in cancer development. Semin Cancer Biol 2005; 15:51-60.

25. Narayan S, Roy D. Role of APC and DNA mismatch repair genes in the development of colorectal cancer. Mol Cancer 2003; 2:41(1-15).

26. Woodford-Richens KL, Rowan AJ, Gorman P, Halford S, Bicknell DC, Wasan HS, et al. SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway. Proc Natl Acad Sci USA 2001; 98:9713-23.

27. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-54.

28. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418:934.

29. Oliveira C, Westera JL, Arango D, Ollikainen M, Domingo E, Ferreira A, et al. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet 2004; 13:2303-11.

30. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87:159-70.

31. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002; 62:6451-5.

32. Oliveira C, Pinto M, Duval A, Brennetot C, Domingo E, Espin E, et al. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 2003; 22:1912-96.

33. Koinuma K, Shitoh K, Miyakura Y, Furukawa T, Yamashita Y, Ota J, et al. Mutations of BRAF are associated with extensive MLH1 promoter methylation in sporadic colorectal carcinomas. Int J Cancer 2004; 108:237-42.

34. Wang L, Cunningham JM, Winters JL, Guenthner JC, French AJ, Boardman LA, et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003; 63:5209-12.

35. Deng G, Bell I, Crawley S, Gum J, Terdiman JP, Allen BA, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated MLH1 but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004; 10:191-95.

36. Fujiwara T, Stolker JM, Watanabe T, Rashid A, Longo P, Eshleman JR, et al. Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. Am J Pathol 1998; 153:1063-78.

37. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-45.

38. Shanmugathan M, Jothy S. Apoptosis, anoikis and their relevance to the pathobiology of colon cancer. Pathol Int 2000; 50:273-79.

39. Itzkowitz SH, Yio X. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004; 287:G7-G17.

40. Itzkowitz SH. Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin N Am 2006; 35:533-71.

41. Agoff SN, Brentnall TA, Crispin DA, Taylor SL, Raaka S, Haggitt RC, et al. The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am J Pathol 2000; 157:373-45.

42. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, et al. Nuclear factor-κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998; 115:357-69.

43. Markowitz SD. Aspirin and colon cancer - targeting prevention? N Engl J Med 2007; 356:2195-8.

44. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94:3336-40.

45. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107:1183-88.

46. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55:3785-89.

47. Cappell MS. From colonic polyps to colon cancer: pathophysiology, clinical presentation, and diagnosis. Clin Lab Med 2005; 25:135-77.

48. Schreiber S, Nikolaus S, Hampe H. Activation of nuclear factor-κB in inflammatory bowel diseases. Gut 1998; 42:477-84.

49. Neurath M, Petterson S, Meyer-Zum-Buschenfelde KH, Strober W. Local administration of antisense phosphothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat Med 1996; 2:998-1004.
50. Karin M, Cao Y, Greten FR, Li ZW. NF-kB in cancer: from innocent bystander to major culprit. Nature Rev Cancer 2002; 2:301-10.

51. Yu L-L, Yu H-G, Yu J-P, Luo H-S, Xu X-M, Li J-H. Nuclear factor-κB p65 (RelA) transcription factor is constitutively activated in human colorectal carcinoma tissue. World J Gastroenterol 2004; 10:3255-60.

52. Sudoyo AW. Karakteristik Molekular Kanker Kolorektal pada Usia Muda: Ekspresi MLH1 dan MSH2 sebagai Indikator Instabilitas Mikrosatelit, in Departemen Ilmu Penyakit Dalam. Universitas Indonesia: Jakarta, 2004.

53. Xiong Z, Wu AH, Bender CM, Tsao J-L, Blake C, Shibata D, et al. Mismatch repair deficiency and CpG island hypermethylation in sporadic colon adenocarcinomas. Cancer Epidemiol Biomarkers Prev 2001; 10:799-803.

54. Abdullah M, Utomo AR, Handjari DR, Sjani AF, Fauzi A, Sastranegara F, et al. Asian Oncology Summit, 2010 April 9-11; Bali, Indonesia.

55. Abdullah M, Sudoyo AW, Pranowo BS, Rini D, Sutrisna B, Rani AA. Expression of NF-kB and COX-2 in young versus older patients with sporadic colorectal cancer. Acta Med Indones - Indones. J Intern Med 2009; 41:70-74.

56. Hao X, Bishop AE, Wallace M, Wang H, Willcocks TC, Maclouf J, et al. Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis. J Pathol 1999; 187:295-301.

57. Abdullah M. Jalur inflamasi pada karsinogenesis kolorektal sporadic di Indonesia: Peran NF-κB dan COX-2 serta hubungannya dengan karakteristik klinikopatologis. [Disertasi] Jakarta, Indonesia: Fakultas Pascasarjana Universitas; 2009.

58. Charalambous MP, Maihöfner C, Bhambra U, Lightfoot T, Gooderham NJ. Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-κB and IκB kinase-α in human colorectal cancer epithelial cells. Br J Cancer 2003; 88:1598-604.

59. Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T. Structure of the human cyclooxygenase-2 gene. Biochem J 1994; 302:723-27.

60. Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside PS, Doetschman T. Transforming growth factor beta-1 suppresses non-metastatic colon cancer at an early stage of tumorigenesis. Cancer Res 1999; 59:3379-86.

61. Spring KJ, Zhao ZZ, Karamatic R, Walsh MD, Whitehall VL, Pike T, et al. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology 2006; 131:400-407.

62. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260:816-19.
کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت های کاربردی در تدوین و چاپ مقاله